BioCryst Pharmaceuticals Inc.
BCRX | NASDAQ
$8.94
+$0.18 (+2.05%)
Sep 22, 2026, 11:30 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 940.61M | 885.72M | 874.84M | 599.82M | 557.51M | 503.49M | 450.71M | 412.58M | 382.24M | 355.4M | 331.41M | 317.56M | 306.64M | 289.68M | 270.83M | 238.44M | 203.61M | 188.03M | 157.17M | 114.03M | 79.14M | 32.05M |
Cost of Revenue | 719.42M | 718.37M | 19.8M | 16.02M | 16.73M | 15.63M | 12.32M | 7.83M | 5.74M | 4.99M | 4.66M | 5.52M | 8M | 7.29M | 6.59M | 4.52M | 1.52M | 1.62M | 7.3M | 6.96M | 7.87M | 7.53M |
Gross Profit | 221.2M | 167.34M | 855.03M | 583.8M | 540.78M | 487.86M | 438.39M | 404.75M | 376.5M | 350.41M | 326.75M | 312.04M | 298.64M | 282.39M | 264.23M | 233.92M | 202.09M | 186.42M | 149.87M | 107.07M | 71.26M | 24.52M |
Operating Income | -313.16M | -381.84M | 340.99M | 76.1M | 54.2M | 33.17M | -2.54M | -40.71M | -60.32M | -89.78M | -103.71M | -107.35M | -112.87M | -126.89M | -148.44M | -154.3M | -181.44M | -176.3M | -177.72M | -177.95M | -176.23M | -185.16M |
Interest Income | 9.82M | 9.9M | 10.67M | 11.35M | 12.7M | 13.74M | 14.75M | 15.64M | 16.23M | 16.43M | 15.78M | 14.02M | 11.59M | 8.45M | 5.13M | 2.44M | 686K | 90K | 62K | 576K | 567K | 3.31M |
Pretax Income | -381.19M | -454.18M | 267.39M | -6.62M | -32.19M | -51.18M | -86.95M | -124.13M | -146.5M | -208.58M | -226.23M | -234.53M | -239.71M | -223.13M | -244.38M | -188.44M | -206.25M | -191.44M | -181.81M | -226.78M | -214.09M | -209.5M |
Net Income | -384.67M | -457.98M | 263.86M | -8.78M | -35.71M | -53.47M | -88.88M | -123.82M | -145.93M | -208.59M | -226.54M | -236.35M | -242.72M | -226.25M | -247.12M | -193.35M | -209.64M | -193.97M | -184.06M | -226.78M | -214.09M | -209.5M |
Selling & General & Admin | 337.33M | 360.73M | 348.65M | 333.34M | 315.41M | 289.27M | 266.29M | 250.21M | 235.77M | 225.52M | 213.89M | 199.67M | 185.94M | 172.96M | 159.37M | 144.61M | 142.68M | 130.99M | 118.82M | 104.42M | 86.62M | 74.18M |
Research & Development | 197.76M | 189.18M | 166.13M | 174.37M | 171.18M | 165.42M | 174.64M | 195.25M | 201.05M | 214.67M | 216.57M | 219.72M | 225.58M | 236.33M | 253.3M | 243.62M | 240.85M | 231.73M | 208.81M | 180.63M | 160.91M | 135.53M |
Other Expenses | -335K | -335K | -335K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -36K | -36K | -36K | -36K |
Operating Expenses | 534.75M | 549.57M | 514.44M | 507.7M | 486.58M | 454.69M | 440.93M | 445.46M | 436.82M | 440.19M | 430.46M | 419.39M | 411.52M | 409.28M | 412.67M | 388.22M | 383.53M | 362.72M | 327.59M | 285.01M | 247.49M | 209.67M |
Interest Expense | 75.29M | 75.16M | 78.87M | 89.19M | 94.35M | 97.5M | 98.52M | 98.65M | 101.17M | 105.35M | 108.24M | 110.11M | 107.54M | 102.65M | 99.09M | 91.41M | 80.75M | 70.23M | 59.29M | 46.12M | 35.25M | 24.67M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4.1M | 8.08M | 9.09M | 10.58M | 8.29M | 5.71M | -21.26M | -22.75M | -24.55M |
Cost & Expenses | 1.25B | 1.27B | 533.85M | 523.72M | 503.31M | 470.31M | 453.26M | 453.28M | 442.55M | 445.18M | 435.12M | 424.91M | 419.52M | 416.58M | 419.26M | 392.74M | 385.05M | 364.33M | 334.89M | 291.98M | 255.36M | 217.2M |
Income Tax Expense | 3.49M | 3.81M | 3.53M | 2.16M | 3.52M | 2.29M | 1.93M | -308K | -564K | 4K | 310K | 1.82M | 3.01M | 3.13M | 2.73M | 4.91M | 3.39M | 2.53M | 2.25M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 254.48M | 242.26M | 210.97M | 210.18M | 209.52M | 208.88M | 207.38M | 206.91M | 206.43M | 206.06M | 201.41M | 189.64M | 189.12M | 188.51M | 186.92M | 186.18M | 183.93M | 184.9M | 181.84M | 179.11M | 178.13M | 177.34M |
Shares Outstanding (Diluted) | 265.17M | 242.26M | 219.26M | 219.89M | 219.89M | 215.26M | 207.38M | 206.91M | 206.43M | 206.06M | 201.41M | 189.64M | 189.12M | 188.51M | 186.92M | 186.18M | 185.61M | 184.9M | 181.84M | 179.11M | 178.13M | 177.34M |
EPS (Basic) | -1.44 | -1.73 | 1.25 | -0.05 | -0.18 | -0.26 | -0.43 | -0.61 | -0.73 | -1.07 | -1.18 | -1.25 | -1.29 | -1.21 | -1.33 | -1.05 | -1.15 | -1.07 | -1.03 | -1.27 | -1.20 | -1.20 |
EPS (Diluted) | -1.50 | -1.78 | 1.20 | -0.05 | -0.18 | -0.26 | -0.43 | -0.61 | -0.73 | -1.07 | -1.18 | -1.25 | -1.29 | -1.21 | -1.33 | -1.05 | -1.15 | -1.07 | -1.03 | -1.27 | -1.20 | -1.20 |
EBITDA | -302.87M | -373.25M | 351.3M | 83.87M | 63.44M | 47.59M | 12.81M | -24.12M | -43.86M | -101.68M | -116.34M | -122.79M | -130.57M | -118.95M | -143.85M | -95.82M | -124.44M | -120.3M | -121.74M | -179.87M | -178.12M | -184.12M |
EBIT | -308.91M | -379.02M | 346.26M | 82.57M | 62.16M | 46.32M | 11.56M | -25.48M | -45.33M | -103.23M | -117.99M | -124.42M | -132.17M | -120.48M | -145.29M | -97.03M | -125.49M | -121.22M | -122.52M | -180.65M | -178.84M | -184.83M |
Depreciation & Amortization | 6.04M | 5.77M | 5.04M | 1.3M | 1.28M | 1.27M | 1.25M | 1.36M | 1.47M | 1.56M | 1.66M | 1.63M | 1.6M | 1.53M | 1.44M | 1.21M | 1.05M | 916K | 777K | 786K | 724K | 708K |
Add to Watchlist
Select watchlists to add or remove BCRX